Our cell engineering services cater to both tool/reagent and biological product development requirements. We have strong expertise to generate recombinant/stable cell lines for complex and wide protein class targets such as:
RTKs GPCRs Ion channels Immune modulation ligands/receptors Fc-gamma receptors GPI-anchored TNF-receptor superfamily Cell adhesion molecules Transporters Co-receptors and Reporter genes
We are well-versed in working with different cellular backgrounds such as established cancer cell lines and primary cells. Hard-to-transfect cell lines required for binding studies, functional assays, immunization in vitro/in vivo screening, and efficacy evaluation applications are successfully engineered to achieve the desired attributes.
For biologic programs, we have experience of product development for mAbs, immune-fusion molecules, and cytokines. The typical activities include:
Transfection Selection Limiting dilution Media/feed screening Cell line characterization Research cell banking and Protein production
We have the experience of multiple production platforms.
Cell lines
- Membrane-bound receptor cell lines with expression calibrated clones (low, medium, and high)
- Receptor density measured and clones selected as per end-use requirement
- Knock-In (KI), Knock-Down (KD) and Knock-Out (KO) cell lines using siRNA / shRNA & CRISPR/Cas9 or TALEN technologies
- Single, double, or multiple gene KO / KD in primary and established cell lines
- Inducible cell line using Tet / Cumate inducible system
- Reporter cell lines (Fluorescent protein / Luciferase)
- Orthotopic cell line for in vivo xenograft and imaging applications
- Production cell lines using commercially available systems such as Freedom CHO-S/CHO DG44/CHOZN, and in-house developed lentiviral system
- SARS-CoV-2 pseudo virus generation and neutralization assay
Vector systems
pcDNA series, pLVX and pGIPZ / pTRIPZ lentiviral vector series, pCHO1.0, pOptivec, pGL, and in-house modified vector systems
Transfection methods
Standard (lipid/nanoparticle), electroporation, transposon, and lentiviral transduction
Screening
Flow cytometry, Western blot, PA-HPLC, ELISA, Octet, and ClonePix
Quality control
Thaw test, mycoplasma, clonal stability, receptor density estimation, SE-HPLC and LC-MS analysis
Why Aurigene Cell Line Engineering Services?
Strong framework data recording and traceability
Recombinant cell lines for wide protein classes
In-house lentiviral platform for difficult to express reagent proteins
Extensive experience working with various vector / cell line systems
Virtual Tour
Hyderabad R and D Center
Bangalore R and D Center
Connect with our scientific experts for your drug discovery, development, and manufacturing needs
We understand that clear communication is essential to successful collaborations, and that's why we have a dedicated team that is always ready to help you. Whether you have questions about our services, want to discuss a potential partnership, or simply want to learn more about our company, we're here to help.
Our team of experts is dedicated to providing personalised solutions tailored to your unique needs. So, please don't hesitate to reach out to us. We look forward to hearing from you and helping you achieve your business goals.
Resources
OCTOBER 01, 2024
PROTACs: Research for a life without cancer
PROTACs: Proteolysis-targeting chimeras (PROTACs) are a rapidly evolving field with promising applications in cancer, neurodegenerative diseases, and other conditions where the regulation of protein levels is crucial. PROTACs are a novel class of small molecules designed to target specific proteins for degradation by the ubiquitin-proteasome sys...
Read More
Advancement in personalized medicine and how the CRDMO industry is part of the solution
Personalized medicine is transforming the healthcare landscape by customizing treatment plans to individual patients’ unique genetic, clinical and environmental characteristics. These are effective and less invasive treatments for a wide range of conditions. Contract Research, Development and Manufacturing Organizations (CRDMOs) play an important role...
Read More
Cell Line Development
We enable development of stable and high yielding recombinant Mammalian and Microbial lines. ...
Read More
Case study: Tackling CYP 2C9 inhibition challenges
The Problem: Active compounds in a project were found to be highly potent inhibitors of CYP 2C9 The compounds selectively inhibited CYP 2C9 with IC50 values <100 nM There was no considerable inhibition of the other CYP isoforms Our Mitigation Approach: CYP 2C9 inhibition data was generated for a larger set of co...
Read More
Synthesis of Anti-covid Drug Nirmatrelvir Using Flow Chemistry
2022
Synthesis of the anti-covid therapeutic Nirmatrelvir by using flow chemistry to enhance efficiency of amide to nitrile conversion in a functionally and Stereochemically Embellished environment. ...
Read More-
Discovery of MAP855, an Efficacious and Selective MEK1/2 Inhibitor with an ATP-Competitive Mode of Action.
2005
Mutations in MEK1/2 have been described as a resistance mechanism to BRAF/MEK inhibitor treatment. We report the discovery of a novel ATP-competitive MEK1/2 inhibitor with efficacy in wildtype (WT) and mutant MEK12 models. Starting from a HTS hit, we obtained selective, cellularly active ...
Read More -
Wang-OSO3H catalyzed green synthesis of bioactive isoindolo[2,1- a ]quinazoline-5,11–dione derivatives: An unexpected observation
2005
The sulphonic acid-functionalized Wang resin (Wang-OSO3H) was explored as a polymeric and recov- erable acidic catalyst for the synthesis of isoindolo[2,1- a ]quinazoline-5,11–dione derivatives under green conditions. Thus the Wang-OSO3H ...
Read More -
Polycyclic Aromatic Compounds: A Simple and Efficient [(n-Bu3Sn)2MO4]n Catalyzed Synthesis of Quinazolinones and Dihydroquinazolinones
2005
A novel unprecedented approach for the synthesis of various quinazolinones and dihydroquinazolinones has been using [(n-Bu3Sn)2MO4]n as a catalyst. The reaction has been screened ...
Read More
You are about to leave Aurigene Pharmaceutical Services and affiliates website. Aurigene Pharmaceutical Services assumes no responsibility for the information presented on the external website or any further links from such sites. These links are presented to you only as a convenience, and the inclusion of any link does not imply endorsement by Aurigene Pharmaceutical Services.
If you wish to continue to this external website, click Proceed.
Leaving already?
Don't forget to join us at
CPHI Worldwide 2023.
October 24th-26th, 2023 | Barcelona, Spain
Get ready to accelerate your drug’s journey to the market